Functional Concept – Page 40

AstraZeneca Addresses Safety Concerns Over Andexxa, Discontinues Opioid Use Disorder Drug

8 months ago talkbio0Tagged Andexxa, Anticoagulation Therapy, AstraZeneca, concerns, Opioid Use Disorder, Reversal, Safety, United States Food and Drug Administration

AstraZeneca, Andexxa, FDA, Safety Concerns, Anticoagulation Reversal, Opioid Use Disorder, AZD4041

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following FDA Setbacks

8 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Chronic Kidney Diseases, Clinical Development, commercial, lexicon, restructuring, setbacks, Surgical aspects, United States Food and Drug Administration

Lexicon Pharmaceuticals, FDA setbacks, Clinical development focus, Commercial operations elimination, Sotagliflozin, Type 1 diabetes, Chronic kidney disease, Restructuring

FDA Panel Raises Safety Concerns Over AstraZeneca’s Anticoagulant Reversal Drug Andexxa

8 months ago talkbio0Tagged Andexxa, Anticoagulants, Approved, AstraZeneca, concerns, Groups, Reversal, Safety, United States Food and Drug Administration

AstraZeneca, Andexxa, FDA panel, anticoagulant reversal drug, safety concerns, full approval

Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment

8 months ago talkbio0Tagged Amylin, Calcitonin Receptor, GIP/, GLP-1, muscle mass, Next, Next-generation weight loss therapies, Obesity, Pep2Tango, Peptides, Tetra-receptor, Ventures, Versant

Obesity treatment, Tetra-receptor agonist peptides, GLP-1/ GIP/ amylin/ and calcitonin receptors, Muscle mass preservation, Next-generation weight loss therapies, Versant Ventures, Pep2Tango Therapeutics Inc.

CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy

8 months ago talkbio0Tagged Behring, California, ex vivo, gene therapy, Industry, R&D site closure, SMPX gene, strategic, trends qualifier

CSL Behring, California R&D site closure, ex vivo gene therapy, strategic repositioning, biotech industry trends

Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development

8 months ago talkbio0Tagged Boshoff, Changing, Chris, Leadership, Mikael, Neoplasms, Pfizer, President brand of dental material, R&D, Research and Development, Scientific Officer

Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D

Unlocking Health Equity: Leveraging Comprehensive SDOH Market Insights for Enhanced Treatment, Access, and Adherence

8 months ago talkbio0Tagged Adherence, Adherence (attribute), Data Analytics, Health care facility, Health Equity, Market, outcomes, public health medicine (field), Social Determinants of Health

Social Determinants of Health (SDOH), Health Equity, Market Insights, Treatment Access, Adherence, Healthcare Outcomes, Data Analytics, Public Health

Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels

8 months ago talkbio0Tagged Atherosclerosis, Cardiovascular system, Gene Silencing Therapy, Heart Disease, Interferes with, Lipoprotein(a ), Lp(a ), Muvalaplin, Risk, RNA, zerlasiran

Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease